2 recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Recruiting 2 |
Follow Asp3082: new trials by email Literature Review of Asp3082 trials Research Report on Asp3082
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation Setidegrasib, Docetaxel - Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Recruiting | Astellas Pharma Global Development, Inc. | 356 | 2026-08-19 | 2026-11-09 |
| A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer Setidegrasib, Oxaliplatin, Leucovorin - Pancreatic Cancer, Metastatic Pancreatic Cancer | Phase 3 | Recruiting | Astellas Pharma Global Development, Inc. | 614 | 2026-02-17 | 2026-11-03 |
Carcinoma, Non-Small-Cell Lung (1) · Pancreatic Neoplasms (1)
Astellas Pharma Global Development, Inc. (2)
China (2) · Japan (2) · United States (2) · Brazil (1) · France (1) · Germany (1) · Poland (1) · South Korea (1) · Spain (1) · Taiwan (1) · United Kingdom (1)